Weekly Sepsis Research Analysis
This week’s sepsis literature emphasized mechanistic discoveries that nominate druggable nodes (IGFBP6–PHB2–STAT1/Akt, ENO1–IFITM2–RAP1B–ERK, MacroD1–complex I) with in vivo rescue, plus translational biomarker and precision-phenotyping advances (plasma proteomics, CHI3L1/MMP8). Several preclinical therapeutic strategies (epigenetic, mitochondrial, NET/ENO1 targeting) and repurposing opportunities emerged alongside pragmatic clinical insights (lactate threshold ≈6 mmol/L; albumin prognostication
Summary
This week’s sepsis literature emphasized mechanistic discoveries that nominate druggable nodes (IGFBP6–PHB2–STAT1/Akt, ENO1–IFITM2–RAP1B–ERK, MacroD1–complex I) with in vivo rescue, plus translational biomarker and precision-phenotyping advances (plasma proteomics, CHI3L1/MMP8). Several preclinical therapeutic strategies (epigenetic, mitochondrial, NET/ENO1 targeting) and repurposing opportunities emerged alongside pragmatic clinical insights (lactate threshold ≈6 mmol/L; albumin prognostication; EHR-driven prevention targets). Overall, the week shifts toward targetable immunometabolic and neuro-immune axes and deployable biomarker/tool development to enable precision sepsis trials.
Selected Articles
1. IGFBP6 orchestrates antiinfective immune collapse in murine sepsis via prohibitin-2-mediated immunosuppression.
A translational study integrating multicenter human cohorts with mechanistic in vitro and murine experiments identifies IGFBP6 as a regulator of sepsis outcomes. IGFBP6 binds PHB2 (IGF-independent) to impair STAT1-driven CCL2 transcription and macrophage chemotaxis, and suppresses macrophage bactericidal Akt signaling; genetic or pharmacologic modulation restored chemotaxis, bacterial clearance, and survival in septic mice.
Impact: Uncovers a dual-arm, druggable mechanism (PHB2→STAT1 and Akt suppression) linking a circulating protein to immunosuppression with in vivo rescue, directly enabling biomarker-driven therapeutic development.
Clinical Implications: IGFBP6 merits rapid clinical validation as a diagnostic/prognostic biomarker and the IGFBP6–PHB2–STAT1/Akt axis is a priority for IND-enabling programs (PHB2/STAT1/Akt modulators) in stratified sepsis populations.
Key Findings
- IGFBP6 identified across multicenter human cohorts as associated with sepsis diagnosis/prognosis.
- Mechanism: IGFBP6 binds PHB2 (IGF-independent), inducing PHB2 phosphorylation and impairing STAT1 activation and CCL2 transcription, reducing macrophage chemotaxis.
- PHB2 silencing and STAT1 activation (2-NP) restored CCL2, improved bacterial clearance, and increased survival in septic mice.
- IGFBP6 suppresses macrophage Akt phosphorylation, reducing ROS/IL-1β and phagocytosis; effects reversible by Akt agonist SC79.
2. Myeloperoxidase-anchored ENO1 mediates neutrophil extracellular trap DNA to enhance Treg differentiation via IFITM2 during sepsis.
This mechanistic study shows NETs promote Treg differentiation by anchoring ENO1 (via MPO) on CD4+ T cells and recruiting IFITM2 as a DNA sensor that activates RAP1B–ERK signaling. Pharmacologic ENO1 inhibition dampened NET-induced Treg induction and ameliorated sepsis in mice, identifying a targetable NET→adaptive-immune axis driving immunosuppression.
Impact: Defines a clear NET→Treg molecular pathway (MPO–ENO1→IFITM2→RAP1B–ERK) with in vivo modulation, revealing a previously underappreciated mechanism of sepsis-induced immunosuppression and a concrete target (ENO1) for intervention.
Clinical Implications: ENO1 and IFITM2 pathway components should be validated in patient samples as potential biomarkers, and ENO1 inhibitors progressed toward early-phase trials to test mitigation of sepsis-induced immunosuppression and secondary infection risk.
Key Findings
- NETs interact directly with CD4+ T cells to enhance Treg differentiation and function.
- MPO anchors ENO1 on T cell membranes; ENO1 recruits IFITM2 which senses NET-DNA and activates RAP1B–ERK signaling.
- Pharmacologic ENO1 inhibition attenuated NET-induced Treg differentiation and improved sepsis outcomes in mice.
3. Cardiomyocyte mitochondrial mono-ADP-ribosylation dictates cardiac tolerance to sepsis by configuring bioenergetic reserve in male mice.
Preclinical work shows MacroD1, a cardiomyocyte-enriched mono-ADP-ribosyl hydrolase, modulates mitochondrial complex I activity; genetic or pharmacologic MacroD1 inhibition preserved complex I function via increased Ndufb9 mono-ADP-ribosylation, reduced cardiomyocyte pyroptosis, improved cardiac function, and lowered mortality in LPS and CLP sepsis models.
Impact: Identifies MacroD1 as a mitochondria-focused, druggable regulator of septic cardiomyopathy with a clear mechanistic link to complex I and cardiomyocyte pyroptosis, opening a novel organ-protective intervention route.
Clinical Implications: MacroD1 inhibition is a prioritized translational target for cardioprotection in sepsis; next steps include selective inhibitor development, assessment of sex differences, large-animal PK/PD and safety studies, and validation in human cardiac tissue/organoid models.
Key Findings
- Genetic and pharmacologic MacroD1 inhibition reduced myocardial metabolic impairment, inflammation, dysfunction, and mortality in LPS and CLP models.
- MacroD1 regulates mitochondrial complex I; inhibition preserved complex I activity and cardiomyocyte bioenergetic reserve.
- Enhanced mono-ADP-ribosylation of Ndufb9 linked MacroD1 inhibition mechanistically to reduced cardiomyocyte pyroptosis.